Entasis Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 47
Employees
  • Stock Symbol
  • ETTX
Stock Symbol
  • Share Price
  • $2.61
  • (As of Friday Closing)

Entasis Therapeutics General Information

Description

Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its products candidate includes Zoliflodacin, ETX0282CPDP, and NBP program.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • Boston BioHub
  • 35 Gatehouse Drive
  • Waltham, MA 02451
  • United States
+1 (781) 000-0000

Entasis Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Entasis Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.61 $2.77 $1.72 - $3.88 $132M 47.6M 386K -$0.97

Entasis Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 102,630 27,895 19,181 (40,705)
Revenue 0 0 7,000 5,000
EBITDA (45,725) (50,528) (44,494) (32,706)
Net Income (45,823) (50,496) (43,850) (32,952)
Total Assets 50,766 61,558 51,034 89,274
Total Debt 864 1,321 1,827 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Entasis Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Entasis Therapeutics‘s full profile, request access.

Request a free trial

Entasis Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is engaged in the discovery, develop
Pharmaceuticals
Waltham, MA
47 As of 2020
00000
000000000 00000

00000000

lla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mol
0000 000000000
Jersey City, NJ
00 As of 0000
00000
000000000 00000

00000000

giat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deser
000000000000000
Watertown, MA
00 As of 0000
00000
000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Entasis Therapeutics Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Scynexis Formerly VC-backed Jersey City, NJ 00 00000 000000000 00000
0000000000 0000000 Formerly VC-backed Watertown, MA 00 00000 000000&0 00000
000000 00000000000 Private Equity-Backed Copenhagen, Denmark 0000 000000000000
00000000000 Formerly VC-backed Rockville, MD 000 00000 000000000 00000
00000 000000000000 Corporation NY 0 00.000 00000000 00.000
You’re viewing 5 of 31 competitors. Get the full list »

Entasis Therapeutics Patents

Entasis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11046694-B2 Compounds and methods for treating bacterial infections Active 08-May-2018 0000000000 00
JP-2020519687-A Compounds and methods for treating bacterial infections Pending 08-May-2017 0000000000
US-20200165251-A1 Compounds and methods for treating bacterial infections Granted 08-May-2017 0000000000
CA-3059773-A1 Compounds and methods for treating bacterial infections Pending 08-May-2017 0000000000
AU-2018266640-A1 Compounds and methods for treating bacterial infections Pending 08-May-2017 A61K31/439

Entasis Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Manoussos Perros Chief Executive Officer & Founder
Michael Gutch Ph.D Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Ruben Tommasi Ph.D Chief Scientific Officer
Anna Triola Chief Commercial Officer
John Mueller Ph.D Executive
You’re viewing 5 of 11 executive team members. Get the full list »

Entasis Therapeutics Board Members (11)

Name Representing Role Since
David Hastings Self Board Member 000 0000
David Meek Self Chairman & Board Member 000 0000
Heather Behanna Ph.D Sofinnova Investments Board Member 000 0000
Howard Mayer Self Board Member 000 0000
Nicholas Galakatos Ph.D Blackstone Life Sciences Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Entasis Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Entasis Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Entasis Therapeutics‘s full profile, request access.

Request a free trial